课题基金 / 基金详情

Guiding treatment decisions in breast cancer with artificial intelligence

Guiding treatment decisions in breast cancer with artificial intelligence
利用人工智能指导乳腺癌的治疗决策
批准号:
10067478
负责人:
金额:
$38.21万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
三阴性乳腺癌(TNBC)是最具侵袭性的乳腺癌,约占所有乳腺癌患者的20%。它对年轻女性和少数民族的影响不成比例,并对生活质量、生育力和工作能力产生深远影响。有压倒性的科学证据表明,TNBC是复杂的,具有不同的临床结果。与许多其他癌症不同的是,目前还没有一种测试能够让我们识别那些有最差结果的人和那些可能有很好结果的人。这意味着我们必须采取‘一刀切’的方法,并建议对大多数患者进行系统化疗。不幸的是,化疗会产生严重的副作用,包括手脚神经受损和危及生命的感染。一些副作用可能是终生的,虚弱的,引起焦虑和影响密切的关系。这种迫切的需要,以改善生活质量和结果导致我们开发了一种新的临床生物标记物测试,称为**SIPA:空间免疫-生态预后评估**。SIPA是一种快速的、人工智能驱动的测试,只需要常规生成的样本。它准确地测量了每个患者对其肿瘤的独特免疫反应,预计它将被常规用于几种组织癌症,以加快精确的医学途径。目前,SIPA主要作为TNBC的一种预测测试,可用于预测哪些患者可能获得最佳结果并免除化疗,同时识别其他可能从免疫治疗等新疗法中受益的患者。最终,我们打算将SIPA用于帮助癌症患者提供个性化治疗的信息。通过这个项目,我们的目标是开发高标准的质量管理系统,在仔细的专家监督下在临床环境中前瞻性地测试SIPA,同时努力制定(体外诊断)IVD CE标志监管计划,准备在英国和欧洲推出。该项目使我们离最大限度地利用尖端的、基于人工智能的技术来造福英国和其他国家的癌症患者又近了一步。SIPA实现的精确患者分层解决了NHS的关键优先事项,并可能彻底改变对TNBC患者的治疗。**我们的附加值是为了患者-防止不必要的毒性和在他们生命中最关键的时刻失去寻求更有效治疗的机会;对于医疗保健提供者--节省潜在无效治疗的巨大成本;对于临床医生--通过使他们能够提供个性化治疗而高效地进行精确肿瘤学。**
英文摘要
Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer, affecting around 20% of all people with breast cancer. It disproportionately affects younger women and ethnic minorities, and has profound effects on quality of life, fertility, and ability to work.There is overwhelming scientific evidence that TNBC is complex with diverse clinical outcomes. Unlike many other cancers, there is currently no test that enables us to identify those at risk of the worst outcomes and those likely to have excellent outcomes. This means that we must take a 'one size fits all' approach and recommend systematic chemotherapy for most patients. Unfortunately, chemotherapy produces significant side-effects, including damage to nerves in the hands and feet and life-threatening infections. Some side effects can be life-long, debilitating, cause anxiety and impact close relationships.This imminent need to improve quality of life and outcomes led us to develop a novel clinical biomarker test known as **SIPA: Spatial Immuno-Ecology Prognostic Assessment**. SIPA is a rapid, artificial intelligence-powered test that only requires routinely generated samples. It accurately measures each individual patient's unique immune response to their tumor, and it is envisaged to be routinely used across several tissue cancers to accelerate precision medicine pathways.Currently, SIPA operates primarily as a prognostication test in TNBC, it can be used to predict which patients are likely to have the best outcomes and be spared chemotherapy, whilst identifying others that may benefit from new treatments such as immunotherapy. Ultimately, we intend for SIPA to be used to help inform personalized therapies for cancer patients.Through this project, we aim to develop high-standard quality management system to prospectively test SIPA in clinical settings under careful expert supervision, whilst working towards an (In-Vitro Diagnostic) IVD CE-mark regulatory plan in preparation to launch in the UK and Europe. This project brings us a step closer to maximize the reach of cutting-edge, AI-based technologies to benefit cancer patients in the UK and beyond. Precise patient stratification enabled by SIPA addresses key NHS priorities and could revolutionize treatment for patients with TNBC.**Our added values are for patients --- prevent unnecessary toxicity and lost opportunities to pursue more effective treatments in the most crucial time of their lives; for healthcare providers --- save tremendous costs on potentially ineffective treatments; and for clinicians ---efficient precision oncology by enabling them to offer personalized treatments.**
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    汪雪玲
  • 依托单位:
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
  • 批准号:
    82371251
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    肖勤
  • 依托单位:
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
  • 批准号:
    82371997
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    张春富
  • 依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究